Medication Use in Frontotemporal Lobar Degeneration (FTLD) as compared to 
Alzheimers Disease (AD)
 
   Lead Investigator:    Adam Boxer
   Institution      :    University of California, San Francisco
   E-Mail           :    aboxer@memory.ucsf.edu
   Proposal ID      :    9


   Publications:


1  Tartaglia MC, Hu B, Mehta K, Neuhaus J, Yaffe K, Miller BL, Boxer A
   Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease
   Journal Article  Alzheimer Dis Assoc Disord,28:182-189,2014,PMC3938980

   PUBLISHED



2  Tartaglia MC, Mehta KM, Hu B, Miller BL, Boxer AL
   Medication Use Differs in Alzheimer's disease and Frontotemporal dementia
   Abstract  Alzheimers Dement,6:S589-S590,2010,

   PUBLISHED





   Proposal Description:
   Study factors related to choice of therapy, including medications.  1. To determine the most common medications and supplements used in patients with frontotemporal lobar degeneration (FTLD) as compared to patients with Alzheimers disease who are matched for demographic variables (age, gender, education, etc.) and disease severity (CDR-SOB, etc.).  2. To determine the relative frequency of FDA-approved AD medication (cholinesterase inhibitor or memantine), antidepressant, mood stabilizer and antipsychotic medication use in FTLD as compared to AD, stratified by disease severity (CDR-SOB) and global cognitive impairment.  3. To determine whether choice or dose of dementia therapy vary by patient characteristics(e.g., age, MMSE score, CDR-SOB).